Prostate therapy could set stage for cataracts

Share this content:

Androgen deprivation therapy (ADT) may increase the risk of cataracts among men with prostate cancer, according to the findings of a large analysis.

ADT can cause weight gain, dyslipidemia, and insulin resistance. These metabolic abnormalities also have been linked with cataracts, leading researchers to question whether this ophthalmologic condition could be another adverse consequence of ADT use.

Jennifer Beebe-Dimmer, PhD, of the Karmanos Cancer Institute in Detroit, and colleagues used the Surveillance, Epidemiology and End Results (SEER; data base to estimate cataract risk associated with ADT among 65,852 men with prostate cancer who had received such therapy (at least one dose of a gonadotropin-releasing hormone agonist or orchiectomy) within 6 months after being diagnosed. After comparing outcomes with men not treated with ADT, the investigators found that gonadotropin-releasing hormone agonist use was associated with a 9% increase in cataract incidence, which they described as “modest” in their online report for Annals of Epidemiology. A 26% increase in cataract incidence was noted among men who had no history of cataracts prior to undergoing orchiectomy.

“In the first systematic investigation of the association between ADT and cataract, our results suggest an elevation in the incidence of cataract among ADT users,” affirmed the authors, who called for further study, preferably of a prospective design, to substantiate or refute their findings.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs